Millennium Management
CLDI icon

Millennium Management’s Calidi Biotherapeutics CLDI Stock Holding History

Millennium Management’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,345
Closed -$157K – 5918
2024
Q4 		$157K Buy
+11,345
New +$213K ﹤0.01% 5382
2024
Q1 		– Sell
-853
Closed -$154K – 6227
2023
Q4 		$154K Buy
+853
New +$229K ﹤0.01% 5241
2022
Q3 		– Sell
-8,718
Closed -$10.4M – 7101
2022
Q2 		$10.4M Buy
8,718
+4,595
+111% +$5.47M 0.01% 1982
2022
Q1 		$4.89M Buy
+4,123
New +$4.87M ﹤0.01% 2961

Other funds holding CLDI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $2.74B AUM 20.71% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
CI
CPR Investments Rochester, Michigan $130M AUM 29.56% 1-Year Est. Return
RWI
Red Wave Investments Dillsburg, Pennsylvania $335M AUM 15.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $517M AUM 16.68% 1-Year Est. Return

Millennium Management's CLDI Position: Q1 2025 in Review

Millennium Management sold out of Calidi Biotherapeutics (CLDI) in Q1 2025, closing a stake of 11,345 shares — an estimated $157K sold.

Millennium Management first reported a position in CLDI in Q1 2022 and held it in 4 quarters. The position peaked at $10.4M in Q2 2022. 35 funds tracked by Wall St. Rank hold CLDI as of Q1 2025.

  • Millennium Management reported no remaining Calidi Biotherapeutics position as of Q1 2025 after selling out during the quarter.
  • Millennium Management sold 11,345 Calidi Biotherapeutics shares in Q1 2025, an estimated $157K.
  • Millennium Management first reported a position in Calidi Biotherapeutics in Q1 2022 and held it in 4 quarters.
  • Millennium Management's Calidi Biotherapeutics position peaked at $10.4M in Q2 2022.
  • 35 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q1 2025.

Based on Millennium Management's 13F filing for Q1 2025, filed 15 May 2025.